FARE's Next Decade: The Mission Continues
May 14, 2022 (McLean, VA) – Food Allergy Research & Education (FARE) is proud of our numerous accomplishments over the past ten years that we have celebrated during Food Allergy Awareness Week with our food allergy community. FARE is acutely aware that as the celebration ends, the mission to end suffering from food allergies continues; and so we will continue our work for the 32 million Americans living with life-threatening food allergies.
Because of FARE, the future for food allergy patients is bright with the promise of better treatments, better care, better access to care, and better overall quality of life. As a research-based advocacy organization, FARE will continue to develop and implement innovative new treatments, programs and strategies to end suffering in the food allergy community. With the power of FARE’s broad and diverse support base, FARE will remain the nation’s leading non-profit engaged in food allergy advocacy. FARE will also continue to lead the food allergy community as the largest funder of food allergy research through raised awareness and understanding of food allergy as a disease, as well as the generous contributions of our friends and corporations.
Here is just a sampling of the goals to which we are aspiring in the next decade:
- Alternative Diagnostics to the Oral Food Challenge: FARE is addressing a major impediment to advancement of new therapeutics by championing the Diagnostic Challenge initiative to foster development of an alternative to the oral food challenge (OFC).
- Advancement of Alternative Approaches to Prevent Food Allergy: Investigators have proposed alternatives to early dietary introduction, which may serve to prevent the development of food allergies in infants.
- Adoption of Early Introduction Guidelines: FARE will meet with Congressional staff on the Senate Agriculture Committee and the House Education and Labor Committee to build support for an early introduction provision as part of the upcoming Child Nutrition Reauthorization Act.
- Championship of New Treatments: FARE continues to monitor the progress of the FARE-sponsored COMBINE study conducted by FCN Investigators at three sites in California. COMBINE is a first-of-its-kind study designed to evaluate the potential beneficial effects of two biologics (omalizumab and/or dupilumab) when used in combination with multi-allergen oral immunotherapy (OIT).
As we prepare for the next decade of breakthroughs, won’t you help us raise awareness of--and dollars for--food allergy research, prevention and treatment? Your support can help greatly improve the quality of life for those affected by life-threatening food allergies. Cheers to a successful Food Allergy Awareness Week past and the hope of a brighter food allergy future to come!
At FARE, we are: Proud of our past. Confident in our present. Optimistic for our future.
FARE is food allergy research and education.
For more information, please visit www.foodallergy.org.
FARE (Food Allergy Research and Education) is the nation’s leading non-profit engaged in food allergy advocacy as well as the largest private funder of food allergy research. FARE’s innovative education, advocacy and research initiatives transform the future of food allergy through new and improved treatments and prevention strategies, effective policies and legislation, and novel approaches to managing the disease. To learn more, visit: foodallergy.org.